head and neck neoplasms/braken

De link wordt op het klembord opgeslagen

Kies het sorteertype

Bladzijde 1 van 303 resultaten

Managing chemotherapy-induced nausea and vomiting in head and neck cancer patients receiving cisplatin chemotherapy with concurrent radiation.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

BACKGROUND The purpose was to retrospectively examine the anti-emetic regimens prescribed for prophylaxis of chemotherapy-induced nausea and vomiting (CINV) for head and neck cancer patients receiving moderate- or high-emetogenic chemotherapy (MEC/HEC) along with concurrent radiation treatment at an

[Control of the emesis induced by cisplatin in patients with head and neck neoplasms. Randomized study of metoclopramide alizapride and placebo].

Alleen geregistreerde gebruikers kunnen artikelen vertalen

A double blind study has been lead on 75 patients affected by head and neck cancer treated with CDDP, to verify the alizapride's antiemetic efficacy versus placebo and metoclopramide. On 76 patients examined, 28 has been treated with CDDP 50 mg/mq + alizapride; 28 with CDDP 50 mg/mq + metoclopramide

Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

BACKGROUND A single-institution, prospective, randomized, open controlled trial was carried out on head and neck cancer patients to compare granisetron (GRA), ondansetron (OND), and tropisetron (TRO) in the prevention of cisplatin-induced acute nausea and vomiting. All patients were

Comparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

OBJECTIVE To compare the antiemetic combination of palonosetron, dexamethasone, and aprepitant (PDA) with antiemetic combination of ondansetron and dexamethasone (OD) in head and neck cancer patients receiving docetaxel, carboplatin, and 5-FU based chemotherapy. METHODS Sixty previously untreated

Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

A phase III, single-institution, open, prospective, randomized, parallel study was carried out on head and neck cancer patients to compare a combination of low-dose (20 mg q.i.d.) oral metoclopramide (M) + i.m. Dexamethasone (D) with an oral 5-HT3-Receptor Antagonist (5-HT3-RA) alone in the

Impact of aprepitant on emesis control, dose intensity, and recurrence-free survival in a population-based cohort of head and neck cancer patients receiving high-dose cisplatin chemotherapy.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

BACKGROUND Standard care for locally advanced head and neck cancer (HNC) patients consists of high-dose cisplatin with radiation to prolong recurrence-free survival (RFS). However, poorly controlled emesis can compromise optimal dose intensity (DI) and affect disease control. OBJECTIVE To evaluate

Factors associated with radiation-induced nausea and vomiting in head and neck cancer patients treated with intensity modulated radiation therapy.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

OBJECTIVE To investigate factors associated with radiation-induced nausea and vomiting (RINV) in the setting of head and neck intensity modulated radiation therapy (IMRT). METHODS Forty-three patients treated with IMRT for head and neck cancer between 2002 and 2007 comprise the cohort. The majority

Correlation between delivered radiation doses to the brainstem or vestibular organ and nausea & vomiting toxicity in patients with head and neck cancers - an observational clinical trial.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

OBJECTIVE Today intensity modulated radiation therapy (IMRT) can be considered the standard of care in patients with head and neck tumors. IMRT treatment plans are proven to reduce acute treatment related side effects by optimal sparing of organs at risk (OAR). At the same time, areas that were out

Low-dose dexamethasone with fosaprepitant and palonosetron to prevent cisplatin-induced nausea and vomiting in head and neck cancer patients.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

OBJECTIVE To determine if a lower dose of dexamethasone can be used in combination with fosaprepitant and palonosetron for cisplatin-induced nausea and vomiting in head and neck cancer patients, we conducted a single-center, two-arm, cross-over comparison study. METHODS Patients were randomly

Trajectory and risk factors for chemotherapy-induced nausea and vomiting in Asian patients with head and neck cancer.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

BACKGROUND The purpose of this study was to analyze the trajectory of and risk factors for chemotherapy-induced nausea and vomiting in Asian patients with head and neck cancer. METHODS Adult patients with head and neck cancer scheduled to receive cisplatin-based chemotherapy were recruited for the

GSTP1 c.313A>G, XPD c.934G>A, XPF c.2505T>C and CASP9 c.-1339A>G Polymorphisms and Severity of Vomiting in Head and Neck Cancer Patients treated with Cisplatin Chemoradiation.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

Cisplatin (CDDP) chemotherapy associated with radiation (RT) has been used in advanced head and neck squamous cell carcinoma (HNSCC) patients, and vomiting is a common side effect during treatment. This prospective study aimed to identify the roles of GSTM1 and GSTT1 (presents or nulls), GSTP1

Radiation-induced nausea and vomiting in head and neck cancer: Is it something worth considering in the intensity modulated radiotherapy era? "A narrative review".

Alleen geregistreerde gebruikers kunnen artikelen vertalen

Radiation therapy is one of the cornerstones in the treatment of head and neck squamous cell carcinomas (HNSCC), alone or in combination with chemotherapy or surgery. Technological advances which occurred over the last few decades have increased the efficacy of radiotherapy (RT), particularly,

Comparison of Granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer. A randomized controlled trial.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

Olanzapine administration for refractory emesis of cisplatin with radiation therapy for head and neck cancer.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

On November 7, 2011, the U.S. Food and Drug Administration approved cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. Approval was based on a randomized

Vorige
1
2
3
4
5
6
...
20
21
De volgende

Word lid van onze
facebookpagina

Herbal & Natural Medicine

De meest complete database met geneeskrachtige kruiden, ondersteund door de wetenschap

Werkt in 55 talen
Kruidengeneesmiddelen gesteund door de wetenschap
Kruidenherkenning door beeld
Interactieve GPS-kaart - tag kruiden op locatie (binnenkort beschikbaar)
Lees wetenschappelijke publicaties met betrekking tot uw zoekopdracht
Zoek medicinale kruiden op hun effecten
Organiseer uw interesses en blijf op de hoogte van nieuwsonderzoek, klinische onderzoeken en patenten

Typ een symptoom of een ziekte en lees over kruiden die kunnen helpen, typ een kruid en zie ziekten en symptomen waartegen het wordt gebruikt.
* Alle informatie is gebaseerd op gepubliceerd wetenschappelijk onderzoek